

**Request for Prior Authorization EXTENDED RELEASE FORMULATIONS**  **FAX Completed Form To** 1.833.404.2392

Pharmacy Help Desk 1.800.460.8988

**Prescriber Help Desk** 

|                                     | (PLEASE PRINT – ACCURACY IS IMPORTA                | NT) 1.833.587.2012             |
|-------------------------------------|--|--------------------------------|
| IA Medicaid Member ID #             | Patient name                                       | DOB                            |
| Patient address                     |  |                                |
| Provider NPI                        | Prescriber name                                    | Phone                          |
| Prescriber address                  |  | Fax                            |
| Pharmacy name                       | Address  | Phone                          |
| Prescriber must complete all inform | ation above. It must be legible, correct, and comp | lete or form will be returned. |
| Pharmacy NPI                        | Pharmacy fax ND                                    | С                              |

Payment for a non-preferred extended release formulation will be considered when the following criteria for coverage are met: 1) Previous trial and therapy failure with the preferred immediate release product of the same chemical entity at a therapeutic dose that resulted in a partial response with a documented intolerance and 2) Previous trial and therapy failure at a therapeutic dose with a preferred drug of a different chemical entity indicated to treat the submitted diagnosis. The required trials may be overridden when documented evidence is provided that use of these agents would be medically contraindicated.

Prior Authorization is required for the following extended release formulations: Adoxa, Amoxicillin ER, Astagraf XL, Augmentin XR, Cardura XL, Carvedilol ER, Cipro XR, Coreg CR, Doryx, Elepsia XR, Envarsus XR, Fortamet, Glumetza, Gocovri, Gralise, Kapspargo, Keppra XR, Lamictal XR, Luvox CR, Memantine ER, Mirapex ER, Moxatag, Namenda XR, Oleptro, Osmolex ER, Oxtellar XR, pramipexole ER, pregabalin ER, Prozac Weekly, Qudexy XR, Rayos, Requip XL, Rythmol SR, Solodyn ER, topiramate ER, Trokendi XR, Ximino.

| Drug Name:           |           | Strength:    |
|----------------------|-----------|--------------|
| Dosage Instructions: | Quantity: | Days Supply: |

Diagnosis:

Previous therapy with immediate release product of same chemical entity (include strength, exact date ranges, and reason for failure):\_\_\_\_\_

Previous therapy with a preferred drug of a different chemical entity (include strength, exact date ranges, and reason for failure):

Contraindication(s) to using immediate release product and/or a preferred drug of a different chemical entity:

Possible drug interactions/conflicting drug therapies:

## Attach lab results and other documentation as necessary.

| Prescriber signature (Must match prescriber listed above.) | Date of submission |
|--|--------------------|
|  |                    |

**IMPORTANT NOTE:** In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Human Services, that the member continues to be eligible for Medicaid.